Physician profile
David C Jamora
NPI 1538420666
$2,839.10
in general payments reported to CMS, 2019-2025
26 companies · $487 in 2025
The $487 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $304 · 2020: $412 · 2021: $324 · 2022: $307 · 2023: $377 · 2024: $629 · 2025: $487.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,493.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,492.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $548.92 | 2021-2025 | |
| Pfizer INC. | $250.52 | 2021-2025 | |
| Amgen INC. | $242.59 | 2019-2025 | Evenity, Prolia, Prolia |
| Shield Therapeutics INC | $218.34 | 2023-2025 | Accrufer |
| Lilly USA, LLC | $211.43 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Novo Nordisk INC | $186.70 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Astrazeneca Pharmaceuticals LP | $156.40 | 2019-2025 | Airsupra, Farxiga |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $126.53 | 2019-2024 | Xifaxan |
| Boehringer Ingelheim Pharmaceuticals, INC. | $122.50 | 2019-2025 | Jardiance |
| Allergan, INC. | $122.02 | 2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $104.42 | 2022-2025 | |
| Dexcom, INC. | $68.94 | 2022-2025 | Dexcom G6 Transmitter |
| Amarin Pharma, INC. | $60.61 | 2019-2021 | |
| Kowa Pharmaceuticals America, INC. | $44.75 | 2019-2024 | Zoryve |
| Glaxosmithkline, LLC. | $44.03 | 2020-2023 | Shingrix |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $43.65 | 2025 | Voquezna |
| Inspire Medical Systems, INC. | $41.46 | 2024-2025 | Inspire |
| Idorsia Pharmaceuticals US INC | $39.80 | 2022-2023 | Quviviq |
| Biohaven Pharmaceuticals, INC. | $38.53 | 2020-2021 | |
| Sanofi-Aventis U.S. LLC | $38.32 | 2022-2024 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $28.86 | 2025 | Caplyta |
| Novartis Pharmaceuticals Corporation | $25.52 | 2019 | |
| Merck Sharp & Dohme LLC | $22.73 | 2019 | |
| Janssen Pharmaceuticals, INC | $22.51 | 2019-2020 | |
| Ironwood Pharmaceuticals, INC | $15.28 | 2020 | |
| Teva Pharmaceuticals USA, INC. | $13.74 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Jamora listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.